Form 4: 180 Life Sciences Director Stephen Shoemaker's Stock Options Vest Early, Pending Shareholder Approval

Stephen H. Shoemaker, a Director at 180 Life Sciences Corp., had 165,000 non-qualified stock options with an exercise price of $0.929 per share accelerate their vesting on July 12, 2025, subject to stockholder approval of the Company's 2025 Option Incentive Plan.

Summary

• Stephen H. Shoemaker, a Director of 180 Life Sciences Corp. (ATNF), reported changes in his beneficial ownership.
• He directly owns 132,439 shares of Common Stock.
• He also directly holds 165,000 non-qualified stock options, which have an exercise price of $0.929 per share and an expiration date of June 17, 2035.
• On July 12, 2025, the Board of Directors, following a recommendation from the Compensation Committee, approved the accelerated vesting of all 165,000 options.
• These options were originally scheduled to vest in two equal tranches on December 17, 2025, and June 17, 2026.
• The accelerated vesting is contingent upon stockholder approval of the Company's 2025 Option Incentive Plan; if this approval is not obtained, the options cannot be exercised and will be cancelled.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The accelerated vesting benefits the director and aligns interests, but the contingency on shareholder approval introduces a degree of uncertainty for the company.

Positives

• Accelerated vesting of 165,000 non-qualified stock options for Director Stephen H. Shoemaker, effective July 12, 2025, potentially increasing his immediate beneficial ownership and aligning his interests more closely with shareholders.

Negatives

• The accelerated vesting of 165,000 stock options is contingent upon stockholder approval of the Company's 2025 Option Incentive Plan; if approval is not obtained, the options will be cancelled and cannot be exercised.

Risks

• Risk of cancellation of 165,000 stock options if stockholder approval for the Company's 2025 Option Incentive Plan is not obtained.

Future Outlook

The future exercise of the 165,000 accelerated stock options is dependent on obtaining stockholder approval for the Company's 2025 Option Incentive Plan.

Management Comments

• The Board of Directors, with the recommendation of the Compensation Committee, approved the accelerated vesting of all options effective July 12, 2025.

Industry Context

This Form 4 filing is a standard disclosure of insider trading activity, specifically related to changes in beneficial ownership of equity securities. Accelerated vesting of stock options is a common corporate governance practice used to incentivize and retain key personnel, though it often requires specific approvals to ensure alignment with shareholder interests.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased alignment with management if the 2025 Option Incentive Plan is approved, but also potential for future dilution if options are exercised.
• Management/Director: Stephen H. Shoemaker benefits from immediate vesting of his options, subject to stockholder approval.

Next Steps

• Obtain stockholder approval for the Company's 2025 Option Incentive Plan.

Key Dates

Keywords

ATNF, 180 Life Sciences, Form 4, SEC filing, beneficial ownership, stock options, accelerated vesting, corporate governance, director compensation, equity compensation